	US 12,016,958 B2
	Method for delivering an agent to posterior segment of an eye and uses thereof
Cheng-Hsun Wu, Zhubei (TW); Si-Han Wu, Taoyuan (TW); Yi-Ping Chen, Keelung (TW); Rong-Lin Zhang, Ligang Township (TW); Tien-Chun Yang, New Taipei (TW); Chung-Yuan Mou, Taipei (TW); and Hardy Wai Hong Chan, New Taipei (TW)
Assigned to NANO TARGETING & THERAPY BIOPHARMA INC., Taipei (TW)
Filed by NANO TARGETING & THERAPY BIOPHARMA INC., Taipei (TW)
Filed on Feb. 25, 2022, as Appl. No. 17/681,121.
Claims priority of provisional application 63/154,091, filed on Feb. 26, 2021.
Prior Publication US 2022/0273583 A1, Sep. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/51 (2006.01); A61K 9/00 (2006.01); A61P 27/02 (2006.01); B82Y 30/00 (2011.01)

CPC A61K 9/5192 (2013.01) [A61K 9/0048 (2013.01); A61P 27/02 (2018.01); B82Y 30/00 (2013.01)]

16 Claims

1. A method for delivering an agent to posterior segment of an eye comprising administrating a pharmaceutical composition comprising the agent and mesoporous silica nanoparticles to the eye, wherein the agent is loaded by mesoporous silica nanoparticles, and an average hydrodynamic diameter of the mesoporous silica nanoparticles or an average hydrodynamic diameter of the mesoporous silica nanoparticles loaded with the agent is less than 60 nm measured in phosphate buffered saline (PBS) by dynamic light scattering.